Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories. The Specialty segment is involved in the development, promotion, distribution, and sale of branded pharmaceutical products with focus on central nervous system disorders, endocrinology, parasitic infections, and other therapeutic areas. It also offers Emverm, a chewable tablet for the treatment of pinworm, whipworm, common roundworm, common hookworm, and American hookworm in single or mixed infections; Rytary to treat Parkinson's disease; and Unithroid for the treatment of hypothyroidism.[ Read More ]
The intrinsic value of one AMRX stock under the base case scenario is HIDDEN Compared to the current market price of 8.47 USD, Amneal Pharmaceuticals, Inc. is HIDDEN
Current Assets | 1.38 B |
Cash & Short-Term Investments | 91.5 M |
Receivables | 646 M |
Other Current Assets | 641 M |
Non-Current Assets | 2.09 B |
Long-Term Investments | 37.1 M |
PP&E | 550 M |
Other Non-Current Assets | 1.51 B |
Current Liabilities | 847 M |
Accounts Payable | 146 M |
Short-Term Debt | 228 M |
Other Current Liabilities | 473 M |
Non-Current Liabilities | 2.56 B |
Long-Term Debt | 2.52 B |
Other Non-Current Liabilities | 41.8 M |
Revenue | 2.39 B |
Cost Of Revenue | 1.57 B |
Gross Profit | 821 M |
Operating Expenses | 616 M |
Operating Income | 204 M |
Other Expenses | 253 M |
Net Income | -48.7 M |
Net Income | -48.7 M |
Depreciation & Amortization | 229 M |
Capital Expenditures | -69.2 M |
Stock-Based Compensation | 26.8 M |
Change in Working Capital | -47.2 M |
Others | 232 M |
Free Cash Flow | 276 M |
Date | Value | Insider | Amount | Avg Price |
---|---|---|---|---|
3 months ago
Aug 14, 2024
|
Sell 176 K USD
|
BOYER ANDREW S
Executive Vice President |
- 22486
|
7.81 USD |
3 months ago
Aug 15, 2024
|
Sell 316 K USD
|
BOYER ANDREW S
Executive Vice President |
- 40225
|
7.85 USD |
3 months ago
Aug 14, 2024
|
Sell 775 K USD
|
Shah Nikita
Executive Vice President |
- 100000
|
7.75 USD |
6 months ago
May 16, 2024
|
Sell 98.4 K USD
|
Autor Deborah M.
Director |
- 14553
|
6.76 USD |
6 months ago
May 17, 2024
|
Sell 158 K USD
|
Autor Deborah M.
Director |
- 23447
|
6.727 USD |
1 year ago
Aug 11, 2023
|
Sell 121 K USD
|
BOYER ANDREW S
Executive Vice President |
- 29302
|
4.1267 USD |
1 year ago
Dec 12, 2022
|
Sell 9.1 M USD
|
TPG GP A, LLC
Director |
- 3884600
|
2.3414 USD |
2 years ago
Dec 17, 2021
|
Bought 210 K USD
|
Patel Gautam
Director |
+ 50000
|
4.21 USD |
2 years ago
Dec 15, 2021
|
Sell 7.9 K USD
|
Shah Nikita
Executive Vice President |
- 2000
|
3.95 USD |
3 years ago
Mar 15, 2021
|
Sell 249 K USD
|
Shah Nikita
Executive Vice President |
- 36330
|
6.8673 USD |
4 years ago
May 19, 2020
|
Bought 44 K USD
|
Kiely John
Director |
+ 10000
|
4.4 USD |
4 years ago
May 15, 2020
|
Bought 99 K USD
|
George Jeffrey P.
Director |
+ 23810
|
4.16 USD |
4 years ago
Mar 18, 2020
|
Bought 553 K USD
|
MEISTER PAUL M
Director |
+ 204210
|
2.71 USD |
4 years ago
Mar 17, 2020
|
Bought 417 K USD
|
MEISTER PAUL M
Director |
+ 149439
|
2.79 USD |
4 years ago
Mar 03, 2020
|
Bought 464 K USD
|
Patel Gautam
director, 10 percent owner: |
+ 117889
|
3.94 USD |
4 years ago
Mar 02, 2020
|
Bought 125 K USD
|
Patel Gautam
director, 10 percent owner: |
+ 32111
|
3.88 USD |
5 years ago
Aug 28, 2019
|
Bought 120 K USD
|
Nark Ted C
Director |
+ 50000
|
2.39 USD |
5 years ago
Aug 16, 2019
|
Bought 72.3 K USD
|
Bhadauria Pradeep
SVP, Chief Scientific Officer |
+ 30000
|
2.41 USD |
5 years ago
Aug 07, 2019
|
Bought 193 K USD
|
BOYER ANDREW S
Exec VP, Comm Optns |
+ 66666
|
2.89 USD |
5 years ago
May 15, 2019
|
Bought 59.4 K USD
|
Bhadauria Pradeep
SVP, Chief Scientific Officer |
+ 7000
|
8.48 USD |
5 years ago
May 13, 2019
|
Bought 180 K USD
|
BOYER ANDREW S
Exec VP, Comm Optns |
+ 19000
|
9.46 USD |
5 years ago
Mar 12, 2019
|
Bought 203 K USD
|
BISARO PAUL
Executive Chairman |
+ 17000
|
11.97 USD |
5 years ago
Mar 06, 2019
|
Sell 289 K USD
|
TERRERI PETER R
Director |
- 23345
|
12.39 USD |
6 years ago
Aug 21, 2018
|
Sell 1.17 M USD
|
Shah Nikita
SVP, Chief HR Officer |
- 50000
|
23.46 USD |
6 years ago
Aug 21, 2018
|
Sell 277 K USD
|
Reasons Bryan M.
CFO |
- 11698
|
23.65 USD |